…a good choice for elderly ovarian cancer patients Evaluating Olaparib for BRCA Wild-Type Platinum-Resistant Ovarian Cancer Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer Niraparib plus bevacizumab significantly…
…a novel based on her great grandmother who carried the BRCA gene mutation. And Morgan Gaynor raised $10,000 on a whim through a Facebook fundraiser. You can create your own Facebook fundraiser in…
…uterine, or colorectal cancer before age 50 Are of Ashkenazi or Eastern European Jewish ancestry, as BRCA mutations are more common among this group Have endometriosis Experience early menstruation What’s…
…found out that I have the BRCA1 gene mutation that put me at a greater risk of breast and ovarian cancer. While no one I knew of in my family…
…of drugs could be expand the use of PARP inhibitors beyond women with BRCA mutations. Suffice to say, it’s an exciting time with lots of potential. Immunotherapy Researchers also spent…
…Roger Greenberg uncovered a new therapeutic target for the regimen of BRCA-mutant cancers. Research in her independent lab integrates several cutting-edge genomics and molecular biology tools to study DNA replication…
Two studies recently released show a survival benefit for intraperitoneal IP chemotherapy Women with the BRCA1 mutation given IP chemotherapy survived three years longer than those given IV chemotherapy. Read…
…research study included genetic testing that resulted in Sam being notified that she carries a BRCA2 gene variant, which is associated with an increased risk of developing ovarian and other…
…long noncoding RNAs, or lncRNAs across 12 cancer types, including ovarian and breast cancers that include the two major BRCA-related cancers. They found that the number of copies of lncRNA…
…of whom also carried other high-risk mutations, such as BRCA or PTEN. “These data provide much-needed insights into the etiology of ovarian cancer and have important implications for prevention, early…
…that can be treated with precision medicine, much in the same way that doctors now know how to treat patients with BRCA mutations using PARP inhibitors. Naming the motivation Rugang…
…for women with platinum-sensitive relapsed ovarian cancer (including fallopian tube or primary peritoneal) with germline BRCA mutation as detected by an FDA-approved test, who are in response (complete response or…
Get email updates about research news, action alerts, and ways to join the fight.
